Specify a stock or a cryptocurrency in the search bar to get a summary
Immunovant Inc
IMVTImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. Address: 320 West 37th Street, New York, NY, United States, 10018
Analytics
WallStreet Target Price
48.15 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IMVT
Dividend Analytics IMVT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IMVT
Stock Valuation IMVT
Financials IMVT
Results | 2019 | Dynamics |